MX2020009403A - Compuestos con actividad anticancer. - Google Patents
Compuestos con actividad anticancer.Info
- Publication number
- MX2020009403A MX2020009403A MX2020009403A MX2020009403A MX2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A MX 2020009403 A MX2020009403 A MX 2020009403A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted azole
- suppress
- cell cycle
- diones
- cancer
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- WIFCKLPZYYALGY-UHFFFAOYSA-N 1h-pyrrole-2,3-dione Chemical class O=C1NC=CC1=O WIFCKLPZYYALGY-UHFFFAOYSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 230000037060 G2 phase arrest Effects 0.000 abstract 1
- 230000006978 adaptation Effects 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/50—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan azol dionas sustituidas novedosas que eliminan células, suprimen la proliferación celular, suprimen el crecimiento celular, anulan el punto de control G2 del ciclo celular y/u ocasionan adaptación a la detención del ciclo celular en G2. Se proporcionan métodos para elaborar y usar los compuestos de la invención. La invención proporciona azol dionas sustituidas para tratar trastornos de proliferación celular. La invención incluye el uso de azol dionas sustituidas para eliminar o suprimir selectivamente células cancerosas sin tratamiento anticáncer adicional. La invención incluye el uso de azol dionas sustituidas que anulan el punto de control G2 del ciclo celular para sensibilizar selectivamente las células cancerosas a reactivos, tratamientos y/u otros tipos de reactivos anticáncer que dañan el ADN.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91125807P | 2007-04-11 | 2007-04-11 | |
| PCT/IB2008/003036 WO2009031040A2 (en) | 2007-04-11 | 2008-04-11 | Compounds with anti-cancer activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009403A true MX2020009403A (es) | 2022-03-31 |
Family
ID=39939984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009403A MX2020009403A (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticancer. |
| MX2009011025A MX2009011025A (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009011025A MX2009011025A (es) | 2007-04-11 | 2008-04-11 | Compuestos con actividad anticancer. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8084454B2 (es) |
| EP (4) | EP3088397B1 (es) |
| JP (2) | JP5635396B2 (es) |
| KR (1) | KR101475311B1 (es) |
| CN (2) | CN101720323A (es) |
| AU (1) | AU2008294410B2 (es) |
| BR (2) | BR122022005149B1 (es) |
| CA (4) | CA3030510C (es) |
| DK (2) | DK2152692T3 (es) |
| ES (3) | ES2732230T3 (es) |
| HK (1) | HK1139143A1 (es) |
| HU (2) | HUE029370T2 (es) |
| IL (4) | IL289165B2 (es) |
| MX (2) | MX2020009403A (es) |
| NZ (1) | NZ580237A (es) |
| RU (1) | RU2482111C2 (es) |
| WO (1) | WO2009031040A2 (es) |
| ZA (1) | ZA200906960B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL289165B2 (en) * | 2007-04-11 | 2024-05-01 | Canbas Co Ltd | Modified azole-dione compounds and pharmaceutical preparations containing them |
| US8227202B2 (en) | 2008-07-10 | 2012-07-24 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| WO2010091198A1 (en) | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| US20100215644A1 (en) * | 2009-02-25 | 2010-08-26 | Nodality, Inc. A Delaware Corporation | Analysis of nodes in cellular pathways |
| CN104744215B (zh) | 2010-03-03 | 2019-03-15 | 尼昂克技术公司 | 包含单萜的药物组合物 |
| CN103168018B (zh) | 2010-08-27 | 2015-10-21 | 尼昂克技术公司 | 包含poh衍生物的药物组合物 |
| US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
| CN103517892B (zh) | 2010-12-17 | 2016-01-27 | 尼昂克技术公司 | 使用异紫苏醇的方法和装置 |
| WO2013020024A2 (en) * | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| US9814693B2 (en) | 2012-05-09 | 2017-11-14 | Delmar Pharmaceuticals, Inc. | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
| WO2013187462A1 (ja) | 2012-06-14 | 2013-12-19 | 第一三共株式会社 | ピペリジニルピラゾロピリジン誘導体 |
| CA2899399A1 (en) | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| WO2016090355A2 (en) * | 2014-12-05 | 2016-06-09 | Massachusetts Institute Of Technology | Catechol-rich polymers from n-substituted maleimides |
| WO2016119051A1 (en) | 2015-01-26 | 2016-08-04 | Ottawa Hospital Research Institute | Compositions and methods for viral sensitization |
| WO2016130800A2 (en) | 2015-02-12 | 2016-08-18 | Neonc Technologies Inc. | Pharmaceutical compositions comprising perillyl alcohol derivatives |
| JP2019513700A (ja) | 2016-03-16 | 2019-05-30 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺有害生物剤及び植物保護剤としてのｎ−（シアノベンジル）−６−（シクロプロピル−カルボニルアミノ）−４−（フェニル）−ピリジン−２−カルボキサミド誘導体及び関連する化合物 |
| USD915100S1 (en) | 2016-03-31 | 2021-04-06 | Ocean 22, Llc | Spooled item holding device |
| USD801721S1 (en) | 2016-03-31 | 2017-11-07 | Patricia Grayson Briden | Spooled item holding device |
| TW201811766A (zh) | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| US20210106522A1 (en) | 2018-01-29 | 2021-04-15 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
| EP3746443B1 (en) | 2018-02-02 | 2022-07-06 | Boehringer Ingelheim International GmbH | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| BR112020013082A2 (pt) | 2018-02-02 | 2020-12-01 | Boehringer Ingelheim International Gmbh | derivados de oxadiazolopiridina benzil-, (piridin-3-il)metil- ou (piridin-4-il)metil- substituídos como inibidores de grelina o-acil transferase (goat) |
| KR20200118084A (ko) | 2018-02-08 | 2020-10-14 | 네온씨 테크놀로지스, 아이엔씨. | 혈액 뇌 장벽의 투과 방법 |
| JP2023526351A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法 |
| JP2023526353A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの連続製造方法 |
| WO2023064888A1 (en) * | 2021-10-15 | 2023-04-20 | The Curators Of The University Of Missouri | Inhibitors of p1b-type atpases |
| CN114425054A (zh) * | 2022-01-20 | 2022-05-03 | 中国人民解放军军事科学院军事医学研究院 | 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5564557A (en) * | 1978-11-08 | 1980-05-15 | Mitsui Toatsu Chem Inc | Diphenyl ether compound and herbicide containing the same |
| IL81307A0 (en) * | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| US5635966A (en) * | 1994-01-11 | 1997-06-03 | Hewlett-Packard Company | Edge feed ink delivery thermal inkjet printhead structure and method of fabrication |
| JPH07224032A (ja) * | 1994-02-09 | 1995-08-22 | Mitsui Petrochem Ind Ltd | Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤 |
| JPH07244032A (ja) * | 1994-03-01 | 1995-09-19 | Ishikawajima Harima Heavy Ind Co Ltd | 溶接部検査装置 |
| AU726058B2 (en) * | 1995-09-01 | 2000-10-26 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| CA2245029A1 (en) | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
| US6205557B1 (en) | 1998-06-09 | 2001-03-20 | At&T Corp. | Redundant call processing |
| DE59903062D1 (de) * | 1998-11-24 | 2002-11-14 | Basf Ag | Fungizide mittel enthaltend als wirkstoffe pyrrolidone |
| CA2385257A1 (en) | 1999-09-22 | 2001-03-29 | Canbas Co., Ltd. | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| DE50104105D1 (de) * | 2000-02-26 | 2004-11-18 | Basf Ag | Fungizide mittel enthaltend als wirkstoffe pyrrolidone und deren verwendung bei der behandlung von pflanzen |
| JP2002318434A (ja) * | 2001-04-23 | 2002-10-31 | Konica Corp | ハロゲン化銀写真感光材料、処理方法、および画像形成方法 |
| FR2826653B1 (fr) * | 2001-06-29 | 2005-10-14 | Servier Lab | Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2003104181A2 (en) * | 2002-06-06 | 2003-12-18 | Canbas Co. Ltd. | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| WO2005024755A2 (en) * | 2002-12-31 | 2005-03-17 | Deciphera Pharmaceuticals, Llc. | Medicaments for the treatment of neurodegenerative disorders or diabetes |
| US7572816B2 (en) * | 2003-08-01 | 2009-08-11 | Auspex Pharmaceuticals, Inc. | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
| JP3977411B2 (ja) * | 2004-03-10 | 2007-09-19 | 株式会社クレハ | アミン系塩基性化合物とその用途 |
| US7973061B2 (en) * | 2004-03-31 | 2011-07-05 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| JP2008530018A (ja) * | 2005-02-08 | 2008-08-07 | メルク エンド カムパニー インコーポレーテッド | チェックポイントキナーゼ阻害剤 |
| MX2008002363A (es) * | 2005-08-17 | 2008-03-18 | Schering Corp | Ligandos novedosos de cinasa basados en quinolina de alta afinidad. |
| EP1960386A2 (en) | 2005-11-01 | 2008-08-27 | Janssen Pharmaceutica N.V. | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase |
| JP5207964B2 (ja) * | 2006-03-31 | 2013-06-12 | 武田薬品工業株式会社 | 酸分泌抑制薬 |
| US20080221103A1 (en) | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
| IL289165B2 (en) * | 2007-04-11 | 2024-05-01 | Canbas Co Ltd | Modified azole-dione compounds and pharmaceutical preparations containing them |
-
2008
- 2008-04-11 IL IL289165A patent/IL289165B2/en unknown
- 2008-04-11 EP EP16165912.3A patent/EP3088397B1/en active Active
- 2008-04-11 IL IL309201A patent/IL309201A/en unknown
- 2008-04-11 BR BR122022005149-9A patent/BR122022005149B1/pt active IP Right Grant
- 2008-04-11 DK DK08829410.3T patent/DK2152692T3/en active
- 2008-04-11 EP EP08829410.3A patent/EP2152692B9/en active Active
- 2008-04-11 BR BRPI0810911-7A patent/BRPI0810911B1/pt active IP Right Grant
- 2008-04-11 RU RU2009141619/04A patent/RU2482111C2/ru active
- 2008-04-11 ES ES16165912T patent/ES2732230T3/es active Active
- 2008-04-11 DK DK19167943.0T patent/DK3567035T3/da active
- 2008-04-11 EP EP22176177.8A patent/EP4074704A1/en active Pending
- 2008-04-11 CN CN200880019414A patent/CN101720323A/zh active Pending
- 2008-04-11 NZ NZ580237A patent/NZ580237A/en unknown
- 2008-04-11 CA CA3030510A patent/CA3030510C/en active Active
- 2008-04-11 AU AU2008294410A patent/AU2008294410B2/en active Active
- 2008-04-11 US US12/082,643 patent/US8084454B2/en active Active
- 2008-04-11 WO PCT/IB2008/003036 patent/WO2009031040A2/en active Application Filing
- 2008-04-11 KR KR1020097023566A patent/KR101475311B1/ko active IP Right Grant
- 2008-04-11 JP JP2010502609A patent/JP5635396B2/ja active Active
- 2008-04-11 EP EP19167943.0A patent/EP3567035B1/en active Active
- 2008-04-11 HU HUE08829410A patent/HUE029370T2/hu unknown
- 2008-04-11 ES ES19167943T patent/ES2927954T3/es active Active
- 2008-04-11 CA CA2913840A patent/CA2913840C/en active Active
- 2008-04-11 ES ES08829410.3T patent/ES2594704T3/es active Active
- 2008-04-11 CA CA2684037A patent/CA2684037C/en active Active
- 2008-04-11 HU HUE19167943A patent/HUE059861T2/hu unknown
- 2008-04-11 CN CN201510578313.XA patent/CN105175394B/zh active Active
- 2008-04-11 MX MX2020009403A patent/MX2020009403A/es unknown
- 2008-04-11 MX MX2009011025A patent/MX2009011025A/es unknown
- 2008-04-11 CA CA3188320A patent/CA3188320A1/en active Pending
-
2009
- 2009-10-06 ZA ZA2009/06960A patent/ZA200906960B/en unknown
- 2009-10-11 IL IL201380A patent/IL201380A0/en active IP Right Grant
-
2010
- 2010-05-25 HK HK10105115.7A patent/HK1139143A1/zh unknown
- 2010-11-19 US US12/950,297 patent/US8415357B2/en active Active
-
2013
- 2013-08-28 JP JP2013176324A patent/JP2014012706A/ja not_active Withdrawn
-
2015
- 2015-12-02 IL IL242883A patent/IL242883B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011025A (es) | Compuestos con actividad anticancer. | |
| EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
| JO2872B1 (en) | New vehicles | |
| TW200942552A (en) | Combination therapy with c-Met and HER antagonists | |
| EA201690994A1 (ru) | Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком | |
| BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
| MY164480A (en) | Inhibitors of akt activity | |
| BRPI0611670A2 (pt) | método para o tratamento ou prevenção de câncer em um indivíduo | |
| WO2008137867A3 (en) | Compositions comprising mir34 therapeutic agents for treating cancer | |
| TN2010000096A1 (en) | Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors | |
| WO2011038210A3 (en) | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009004047A (es) | Compuestos organicos. | |
| MX2009012623A (es) | Moduladores de cinasa heterociclicos. | |
| MX2009009761A (es) | Composiciones y estuches para tratamiento de la influenza. | |
| WO2011143318A3 (en) | Anti-fgfr2 antibodies | |
| MX351083B (es) | Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales. | |
| TR200906131T1 (tr) | Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e | |
| PL2231636T3 (pl) | Pochodne pirazolowe i ich zastosowanie jako inhibitorów kinaz zależnych od cyklin | |
| EA201070609A1 (ru) | Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств | |
| IN2012DN02471A (es) | ||
| EA201100874A1 (ru) | Соединения для лечения рака | |
| WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
| MX2008001428A (es) | Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos. | |
| MX2009009693A (es) | Metodos para activar irs-1 y akt. |